Background: Reactions between nitric oxide (NO), nitrite (NO
mediate anti-inflammatory responses both in vitro and in vivo. For example, OA-NO 2 and LNO 2 inhibit NF-jB signal transduction by blocking p65 DNA binding, thereby suppressing multiple pro-inflammatory cytokines. Similarly, in LPS-stimulated macrophages, OA-NO 2 suppresses the secretion of IL-6, TNF-a, and MCP-1 in an NF-jB-dependent manner (2) . In vivo, OA-NO 2 has been shown to prevent vascular NF-jB activation and subsequent TLR4 surface recruitment following LPS stimulation (3) . Additionally, NO 2 -FAs stimulate anti-inflammatory, antioxidant, and cytoprotective gene expression by acting as partial agonist of peroxisome proliferator-activated receptor-c (PPAR-c) and activating heme oxygenase-1 (HMOX-1), nuclear factor E2-related factor 2 (Nrf2), and the heat-shock response pathways (4) (5) (6) (7) . The beneficial health effects and therapeutic potential of NO 2 -FAs have been demonstrated in several in vivo murine models of inflammatory disease. In this regard, administration of OA-NO 2 attenuated endotoxemia, renal ischemia and reperfusion injury, angiotensin II-induced hypertension, and atherosclerosis (8) (9) (10) (11) . Thus, there is considerable interest in employing NO 2 -FAs and other electrophilic fatty acids (EFAs) for the prevention and treatment of inflammatory disorders.
Allergic contact dermatitis (ACD) is a delayed-type hypersensitivity response and one of the most common cutaneous inflammatory diseases, affecting as many as 15-20% of the population worldwide. ACD is an antigen-specific T cellmediated cutaneous inflammatory disease typically triggered through hapten sensitization and elicitation. Hapten exposure results in the secretion of a variety of inflammatory mediators in skin in vivo and activates NF-jB pathways in human and mouse cutaneous dendritic cells (12) (13) (14) . Based on this rationale, we evaluated potential anti-inflammatory effects of NO 2 -FAs in a murine model of ACD.
Materials and methods

Mice
Female Balb/c mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA) and used between the ages of 6 and 12 weeks. Male and female Foxp3 tm3(DTR/GFP)Ayr (FoxP3 DTR ) mice on the C56Bl/6 background (15), developed and granted by Alexander Rudensky and a kind gift by Dario Vignali, were bred and housed in the University of Pittsburgh animal facility. Mice were housed under specific pathogen-free conditions and treated according to the University of Pittsburgh's institutional animal care guidelines and according to the NIH guide for the care and use of laboratory animals.
Chemicals and reagents
10-OA-NO 2 and NO 2 -13 C 18 OA were synthesized and purified as previously described (16, 17) . The concentration of 10-OA-NO 2 was calculated gravimetrically or spectrophotometrically using the following extinction coefficient in phosphate buffer, pH 7.4, k 268 8.22. 
Contact hypersensitivity response
Cutaneous microscopy
To assess histology and cellular infiltration, cross sections of mouse ears were prepared and stained as previously described (18) . Briefly, frozen cross sections were embedded in TissueTek OCT (Miles Laboratories, Elkhart, IN, USA) and snapfrozen in prechilled methyl-butane (Sigma-Aldrich). Cryostat sections (8 lm) were mounted onto slides pretreated with Vectabond (Vector Laboratories, Burlingame, CA, USA), fixed in 96% EtOH, and used for H&E staining. Images were acquired using an Olympus Provis AX-70 microscope system (Olympus, Melville, NY, USA) with FluoView 500 software.
Regulatory T-cell ablation
To ablate regulatory T cells (Treg), FoxP3 DTR mice were intraperitoneally (i.p.) injected with 50 lg/kg diptheria toxin (DT) (Sigma-Aldrich) on day 1 (day 1 is determined according to Fig. 1A ) and then every other day until day 9. In these experiments, control mice were FoxP3 DTR littermates not treated with DT.
Statistical analysis
Results from multiple different groups were compared using a two-way analysis of variance (ANOVA) followed by the Bonferroni post hoc test to compare groups over time. A one-way ANOVA was utilized followed by Newman-Keuls multiple comparison post hoc test if only one time point was assessed. Comparison of two means was performed by a two-tailed Student's t-test. A P value of <0.05 was considered statistically significant.
Results
Bioavailability of OA-NO 2
To assess the capacity of OA-NO 2 to access the systemic circulation following SC injection, we determined OA-NO 2 serum levels over time after treatment. Initially, titrations of OA-NO 2 were performed from 0.01% to 1%, and 0.1% OA-NO 2 was selected as the highest dose that did not induce a local irritant effect (data not shown). 0.1% OA-NO 2 (NO 2 -18 : 1) was injected SC (two injection sites, 100 ll each) and it and its major metabolites (NO 2 -16 : 1 and NO 2 -14 : 1) were quantified in the serum 3, 6, and 18 h following SC injections. OA-NO 2 was present in the circulation and active based on the metabolites detected (Fig. S1 ). Importantly, physiologically relevant levels of OA-NO 2 (3) were detected as early as 3 h following injection of 0.1% OA-NO 2 , and levels were sustained within the physiological range for at least 18 h following treatment (Fig. S1 ). Overall, these data confirm the bioavailability of SC-administered OA-NO 2 for at least 18 h following treatment.
Induction of cutaneous inflammatory immune responses are inhibited by OA-NO 2
To determine whether OA-NO 2 can inhibit a cutaneous inflammatory response, we established CHS as a murine model of ACD in Balb/c mice utilizing the hapten DNFB. The effect of OA-NO 2 on CHS induction was determined by injecting mice SC at a distal site with OA-NO 2 18 h prior to abdominal sensitization with DNFB, then again 5 days later and 18 h prior to DNFB elicitation of the CHS response in the ear (Fig. 1A) . We chose to treat mice with OA-NO 2 18 h prior to DNFB sensitization and elicitation based on our pharmacokinetic studies that indicated the presence of physiologically relevant levels of OA-NO 2 within 18 h, enabling sufficient time to initiate anti-inflammatory responses prior to hapten exposure. CHS, assessed by increases in ear thickness, was significantly decreased in OA-NO 2 -treated mice at 48 and 72 h following elicitation, compared with DNFB treatment alone (Fig. 1B) . Moreover, this response was sustained for at least 144 h postelicitation (Fig. 1C) . Native OA control did not suppress CHS nor did vehicle control (VC) (Fig. 1B) . Histological analysis demonstrated an absence of epidermal micro-abscesses and a decrease in epidermal/dermal thickness and cellular infiltrate in mice treated with OA-NO 2 compared with those administered DNFB alone, or OA or VC controls ( Fig. 1D) , consistent with the inhibitory effect observed by ear thickness measurements ( Fig. 1B and 1C ). These results demonstrate the anti-inflammatory electrophilic effects of OA-NO 2 in the cutaneous microenvironment. Seventy-four hours following elicitation, ears were excised and cross sections were stained with H&E. Scale bar = 50 lm. OA-NO 2 , nitro-oleic acid; ACD, allergic contact dermatitis; CHS, contact hypersensitivity; DNFB, 2,4-dinitrofluorobenzene; SC, subcutaneous.
OA-NO 2 suppresses inflammation-induced cutaneous angiogenesis
There is substantial evidence demonstrating the interdependence of angiogenesis and inflammation. In this regard, one of the hallmarks of ACD is increased vascularization and inhibition of vascularization can block CHS (19) . In vivo, OA-NO 2 prevents vascular NF-jB activation (3). Thus, we evaluated the cutaneous expression of the endothelial cell marker CD31 following induction of CHS to determine the effect of SC OA-NO 2 treatment on cutaneous angiogenesis. A significant increase in vascular CD31 expression was observed in the DNFB treatment group 72 h following elicitation, compared with control mice ( Fig. 2A and 2B ). In the presence of OA-NO 2 , CD31 expression was markedly and significantly decreased 72 and 144 h postelicitation, compared with DNFB alone. Moreover, with OA-NO 2 treatment vessels that were present appeared to be collapsed compared with open vessels observed following DNFB alone. Our results demonstrate that OA-NO 2 inhibits vascularization in the setting of ACD, which potentially limits homing of inflammatory cells into the cutaneous microenvironment.
Molecular phenotype of skin following subcutaneous OA-NO 2 injection
To evaluate the molecular effects of OA-NO 2 in the cutaneous microenvironment, mice were treated SC with OA-NO 2 prior to DNFB treatment, and skin was evaluated for changes in gene expression 12 h after elicitation. There was a significant decrease in mRNA expression levels for the inflammatory factor IL-1b in the OA-NO 2 -treated group, compared with those receiving DNFB alone or DNFB + OA control treatment (Fig. 3A) . Furthermore, IL-1b transcripts were suppressed in the skin for at least 72 h (data not shown). IL-6 levels were not decreased by 12 h after elicitation in the presence of OA-NO 2 , compared with DNFB alone. However, IL-6 was significantly increased in the native OA control group compared with both the DNFB and OA-NO 2 treatment groups (Fig. 3B, left panel) . Importantly, 72 h following elicitation, compared with DNFB alone, OA-NO 2 significantly decreased IL-6 expression (Fig. 3B, right  panel) . Thus, OA-NO 2 suppresses pro-inflammatory cytokines at both 12 and 72 h following elicitation. Electrophilic fatty acids inherently initiate antioxidant and cytoprotective gene expression by activating the Nrf2/Keap1/ HMOX-1 pathway, which is the prototypical signaling pathway activated by electrophilic compounds (7, 20) . Thus, we assessed HMOX-1 expression in the skin following SC injections of OA-NO 2 . We observed a significant increase in HMOX-1 12 h after elicitation in the DNFB alone CHS group, which was maintained in the OA-NO 2 treatment group, but significantly suppressed by native OA (Fig. 3A , right panel).
OA-NO 2 enhances regulatory cell functions
In addition to various cutaneous regulatory pathways, Tregs secreting IL-10 play a major role in the resolution of CHS (21) . Thus, we next determined whether OA-NO 2 could potentiate Treg responses in order to resolve inflammation. We first examined the ability of OA-NO 2 to induce IL-10, a regulatory cytokine secreted by CD4
+ regulatory T cells. IL-10 expression was not affected by OA-NO 2 in the first 24 h following elicitation. However, by 72 h after elicitation IL-10 transcripts were significantly increased in OA-NO 2 -treated skin (Fig. 4A) . Subsequently, we examined the presence of Foxp3 + cells in the skin. Seventy-two hours after elicitation, Foxp3 + Tregs accumulate in the skin regardless of OA-NO 2 treatment (Fig. 4B and 4C ). While there was not a significant increase in Tregs at 72 h, there was a significant increase in IL-10 transcript expression, suggesting that OA-NO 2 promoted Treg activation. By 144 h following elicitation, there was a significant increase in dermal Foxp3 + regulatory T cells in OA-NO 2 -treated animals compared with those with DNFB treatment alone ( Fig. 4B  and 4C ). In line with this finding, there was also a significant increase in cutaneous Foxp3 transcript expression (Fig. 4D) . To more specifically evaluate whether enhanced Treg activity contributes to OA-NO 2 -induced CHS inhibition, we evaluated OA-NO 2 effects in Treg-depleted animals. Tregs were depleted by treating FoxP3 DTR mice with 50 lg/kg of DT starting 1 day following sensitization (day 1) and continuing every other day until 4 days following elicitation (day 9) (15). FoxP3 DTR littermates not treated with DT were used as control mice. In FoxP3 DTR mice OA-NO 2 significantly suppressed the CHS response by 48 h postelicitation, as determined by a decrease in ear thickness (Fig. 4E) . However, when Treg cells were depleted by treatment with DT, OA-NO 2 had a minimal effect compared with DNFB treatment alone (Fig. 4E) . Taken together, these results indicate that OA-NO 2 supports Treg accumulation and function in reducing CHS.
OA-NO 2 treatment resolves established CHS responses
Given the observed efficacy of OA-NO 2 in the prevention of CHS, and underlying mechanisms suggestive of a potent antiinflammatory effect, we sought to ascertain the effectiveness of OA-NO 2 in the treatment of established CHS. For this, we first determined whether OA-NO 2 is critical during sensitization and/or elicitation. Mice were sensitized and elicited with DNFB and treated with OA-NO 2 only during either the sensitization phase (SO), elicitation phase (EO), or during sensitization and elicitation (SE). There was a significant decrease in the ear swelling in the EO and SE treatment groups compared with the SO treatment group (Fig. 5A ), indicating that OA-NO 2 is essential only during the elicitation phase, and it suggests that OA-NO 2 could be effective therapeutically. To address this directly, we sought to determine whether OA-NO 2 has the capacity to suppress an established CHS response. Mice were sensitized (day 0) and elicited (day 5) with DNFB. Forty-eight hours following elicitation (day 7), mice were treated with OA-NO 2 , VC, or left untreated. Ear thickness was measured 24 h after elicitation (day 6) and again at 48 h (day 7, treatment day 0), 72 h (day 8, post-treatment day 1), and 144 h (day 11, post-treatment day 4) after elicitation. Within 24 h following OA-NO 2 injection, there was a significant decrease in ear swelling in the OA-NO 2 -treated group compared with untreated animals and VCs (Fig. 5B) . Over the subsequent 3 days, significant ear swelling persisted in VC and untreated animals, while ear swelling was reduced to near baseline in OA-NO 2 -treated animals. Taken together, these results demonstrate that OA-NO 2 has the capacity to therapeutically suppress established CHS.
Discussion
The therapeutic potential of NO 2 -FAs has been demonstrated in several in vivo murine models of inflammatory disease. Herein, we reveal that a distant SC injection of an exemplary NO 2 -FA, OA-NO 2 , can prevent and treat CHS in mice. NO 2 -FAs appear to affect multiple immune regulatory mechanisms in the skin. First, OA-NO 2 reduced IL-1b and IL-6, essential pro-inflammatory cytokines for the differentiation of Th17 cells involved in ACD (22) . This reduced cytokine expression is consistent with the capacity of EFAs to inhibit inflammation through the blockade of NF-jB translocation and downstream expression of IL-1b and IL-6 (3, 8) . Specifically, OA-NO 2 and LNO 2 inhibit NF-jB signal transduction at various signaling stages by disrupting the upstream assembly of adaptor protein complexes (TRAF6/IKKb/IjBa) in lipid rafts and blocking IjBa phosphorylation and p65 DNA binding, thereby suppressing multiple pro-inflammatory cytokines (2, 3, 23) . Second, in addition to these cytokine effects, our results demonstrate that OA-NO 2 inhibits vascularization in the setting of ACD. There is substantial evidence demonstrating the interdependence of angiogenesis and inflammation. In this regard, one hallmark of ACD is increased vascularization and inhibition of vascularization can block CHS (19) . By limiting vascularization, OA-NO 2 can limit the homing of inflammatory cells into the cutaneous microenvironment. Third, our studies show that OA-NO 2 affects the accumulation of Tregs in the skin. Tregs secreting IL-10 play a major role in the resolution of CHS (21) . The regulatory mechanisms engaged by Tregs are involved in both suppression of effector T-cell responses in the LNs, and restraining peripheral inflammation in the skin following ACD induction (24) (25) (26) (27) (28) . Consistent with studies by Lehtimaki et al. (27) , we find that Tregs gradually accumulate in the dermis of DNFB-challenged mice, presumably as a compensatory mechanism facilitating inflammatory resolution. Importantly, we show that OA-NO 2 enhances this recruitment of Tregs into inflamed dermis and potentiates the IL-10 response. Electrophilic fatty acids have been shown to inherently initiate antioxidant and cytoprotective gene expression by activating the Nrf2/Keap1/HMOX-1 pathway, which is the One representative of two individual experiments for each study. Asterisk indicates a significant difference between the indicated treatment groups, *P < 0.05, **P < 0.01, and ***P < 0.001. OA-NO 2 , nitro-oleic acid; CHS, contact hypersensitivity; DNFB, 2,4-dinitrofluorobenzene.
prototypical signaling pathway activated by electrophilic compounds (7, 20) . HMOX-1 is induced in response to cellular stress and diverse oxidative stimuli. HMOX-1 contributes to the reduction in oxidative stress and the attenuation of inflammatory responses. We assessed HMOX-1 expression in the skin following SC injections of OA-NO 2 . In the context of the enhanced pro-inflammatory DNFB CHS cytokine response, we observed a significant increase in HMOX-1, in both OA-NO 2 -treated and untreated groups. In vivo, exposure to sensitizers can activate Nrf2 signaling by increasing the levels of reactive oxygen species, other radical species, and lipid oxidation products, a response paralleled by extents of EFA generation (29) . Despite the similarity between these responses, several characteristics differentiate the signaling induced by sensitizers and EFAs. Sensitizers, their metabolites, and by-products of the inflammatory responses are typically harder electrophiles and thus more reactive not only with cysteine but also more readily alkylate lysine, histidine, and DNA bases (30) . Hard electrophile reactions with lysine and histidine are long-lived compared with thiol reactions and are accompanied by both DNA base alkylation and more indiscriminate cysteine reactions. This is an important consideration, as DNA damage furthers inflammation and cell death. As a consequence, the activation of Nrf2 and downstream HMOX-1 expression by sensitizers is accompanied by widespread lysine, histidine, and cysteine adduction that can promote cell toxicity, increased inflammation, and cell death (31) . In contrast, NO 2 -FAs are soft electrophiles that preferentially target Keap1 over other competing cellular thiols, minimally modify histidine, and do not react with lysine (32) . This mechanism of action allows for increased HMOX-1 expression and the attenuation rather than exacerbation of inflammatory responses that would be induced by indiscriminate hard electrophile-mediated alkylation reactions. In addition, EFAs react reversibly with thiols, a characteristic not shared by reactive oxygen species and harder electrophiles, resulting in reduced residency time on target proteins and lower potential for toxicity (30, 33) . Thus, EFAs will inhibit CHS by mechanisms not shared by sensitizers, inhibiting inflammation by limiting NF-jB-dependent proinflammatory mediator expression and promoting Nrf2-dependent NF-jB downregulation (2, 34) . Therefore, while we demonstrate that DNFB induces the HMOX-1 expression to a similar extent as OA-NO 2 , it is important to consider that the environment and underlying conditions resulting from EFAs, actions are mechanistically distinct from and account for the protective actions of OA-NO 2 .
In addition to reversing Nrf2/HMOX-1 pathway activation, native OA potentiated the ACD inflammatory response, characterized by intense epidermal infiltration, thickness, and microabscess formation. There are conflicting reports regarding the role of OA in inflammation. For instance, studies have suggested that OA has an anti-inflammatory role by, in part, inhibiting T-cell activation and proliferation (35) . Contrary to these findings, studies utilizing OA-induced lung injury and peritoneal exudate models suggest that OA enhances inflammatory responses by inducing neutrophil activation and migration to sites of inflammation (36) (37) (38) . In this regard, neutrophils in skin are highly inflammatory and are required for the development of CHS (39) . Thus, in an ACD model the observed enhancement of the inflammatory response in the skin by native OA may be a result of Asterisks indicate a significant difference between indicated groups, **P < 0.01. (B) CHS was induced in mice with 0.5% DNFB. Forty hours following elicitation (arrow), groups of mice received OA-NO 2 and vehicle control, or were untreated. Each data point represents the mean increase in ear thickness AE SEM of 3-5 mice. Asterisk indicates a significant difference compared with DNFB treatment group, *P < .05 and ***P < 0.001. Both data sets are one representative of three independent experiments each. OA-NO 2 , nitro-oleic acid; CHS, contact hypersensitivity; DNFB, 2,4-dinitrofluorobenzene.
attraction and activation of neutrophils, distinct from the observed electrophilic OA-NO 2 suppression of cutaneous infiltration and inflammation.
Importantly, the levels of OA-NO 2 detected in the serum in our studies were physiologically relevant in the context of instigating systemic signaling responses. For instance, Villacorta et al. (3) demonstrated in a murine model of vascular inflammation that 25 nM (8 ng/ml) serum concentrations of OA-NO 2 were sufficient to inhibit NF-jB translocation and DNA binding. In parallel, we observed systemic serum concentrations ranging from 25 to 60 nM (8-20 ng/ml). These levels of OA-NO 2 were sufficient to significantly decrease the expression of the NF-jB-dependent cytokines IL-b and IL-6 in the context of CHS. These murine-based observations have a significant potential to be translated into clinical trials, as the pharmacokinetics of OA-NO 2 have been extensively characterized in multiple animal models in the course of IND-enabling studies of both intravenous and oral formulations of OA-NO 2 for administration to humans. FDA-approved Phase 1a and 1b investigations of both intravenous and oral OA-NO 2 show bioavailability and affirm drug safety, with these human trials exceeding the 25-60 nM serum concentrations that were achieved in the present murine model studies.
In aggregate, the data presented here provide experimental evidence that SC-delivered OA-NO 2 is capable of preventing and treating CHS. In the setting of CHS, OA-NO 2 demonstrates multiple effects on cutaneous immune function. It inhibits the production of inflammatory cytokines and reduces vascularization. Importantly, OA-NO 2 favors the accumulation of functional Tregs in inflamed skin over time, contributing to the resolution of the inflammatory response. Overall, these results support the development of OA-NO 2 as a promising therapeutic for ACD and provides new insights into the role of EFAs in the control of cutaneous immune responses potentially relevant to a broad range of allergic and inflammatory skin diseases.
